Cognition Therapeutics, Inc. (CGTX)
收市後：
| 前收市價 | 1.9400 |
| 開市 | 1.9400 |
| 買盤 | 1.9200 x 100 |
| 賣出價 | 1.9700 x 100 |
| 今日波幅 | 1.8900 - 2.0199 |
| 52 週波幅 | 0.9000 - 3.4900 |
| 成交量 | |
| 平均成交量 | 197,896 |
| 市值 | 78.114M |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.9200 |
| 業績公佈日 | 2024年8月08日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 6.67 |
Insider MonkeyCognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript March 26, 2024 Cognition Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, everyone, and welcome to Cognition Therapeutics Fourth Quarter 2023 Earnings Call. Please note that this call […]
BenzingaA Dose of Hope: Cognition's CT1812 Proves Its Mettle in Alzheimer's Aβ Oligomer Displacement
Cognition Therapeutics Inc (NASDAQ: CGTX) announces data publication from a Phase 1b SNAP trial of CT1812 to Measure Aβ Oligomer Displacement in Alzheimer's Disease in the Translational Neurodegeneration journal. "By evaluating hourly changes in beta-amyloid (Aβ) oligomer concentrations in the cerebrospinal fluid (CSF) of individuals with mild-to-moderate Alzheimer's disease, we were able to observe the impact of CT1812 target engagement," stated Mary Hamby, VP of research. "Data from the Phase
